Literature DB >> 18978110

A protocol of dual prophylaxis for venous thromboembolism prevention in gynecologic cancer patients.

M Heather Einstein1, David M Kushner, Joseph P Connor, Alex A Bohl, Thomas J Best, Michael D Evans, Richard J Chappell, Ellen M Hartenbach.   

Abstract

OBJECTIVE: To evaluate a quality improvement protocol for venous thromboembolism prevention in postoperative gynecologic cancer patients.
METHODS: On January 1, 2006, we initiated a universal protocol of dual prophylaxis with sequential compression devices and three times daily heparin (or daily low molecular weight heparin) until discharge in gynecologic cancer patients having major surgery. Patients with both malignancy and age over 60 years (or history of prior clot) were discharged on 2 weeks of anticoagulant. Before January 2006, all patients were given sequential compression devices starting before the induction of anesthesia, continuing until discharge from the hospital. Records of gynecologic cancer service patients admitted in 2005 and 2006 were reviewed, excluding patients with a history of heparin-induced thrombocytopenia or those admitted on an anticoagulant. Any pulmonary embolism or deep vein thrombosis diagnosed within 6 weeks of surgery was identified. We performed chi2 and Wilcoxon rank sum tests as well as multivariable regression analysis for confounders.
RESULTS: Six of the 311 women meeting inclusion criteria in 2006 (1.9%) and 19 of 294 (6.5%) in 2005 had venous thromboembolism (odds ratio 0.33, 95% confidence interval 0.12-0.88, multivariable analysis adjusting for baseline differences between the groups). Heparin was given to 98.1% of patients in the hospital in 2006, and 91.1% of those meeting high-risk criteria were discharged on an anticoagulant. No differences in major bleeding complications were seen between years.
CONCLUSION: A protocol of dual prophylaxis with prolonged prophylaxis in high-risk patients was successfully implemented and was associated with a significant reduction in the rate of venous thromboembolism without increasing bleeding complications. LEVEL OF EVIDENCE: II.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18978110     DOI: 10.1097/AOG.0b013e31818b1486

Source DB:  PubMed          Journal:  Obstet Gynecol        ISSN: 0029-7844            Impact factor:   7.661


  11 in total

1.  VTE, thrombophilia, antithrombotic therapy, and pregnancy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.

Authors:  Shannon M Bates; Ian A Greer; Saskia Middeldorp; David L Veenstra; Anne-Marie Prabulos; Per Olav Vandvik
Journal:  Chest       Date:  2012-02       Impact factor: 9.410

2.  Incidence and predictors of venous thromboembolism after debulking surgery for epithelial ovarian cancer.

Authors:  Bahareh Mokri; Andrea Mariani; John A Heit; Amy L Weaver; Michaela E McGree; Janice R Martin; Maureen A Lemens; William A Cliby; Jamie N Bakkum-Gamez
Journal:  Int J Gynecol Cancer       Date:  2013-11       Impact factor: 3.437

Review 3.  Prevention of venous thromboembolism in gynecologic oncology surgery.

Authors:  Emma L Barber; Daniel L Clarke-Pearson
Journal:  Gynecol Oncol       Date:  2016-11-25       Impact factor: 5.482

Review 4.  Venous thromboembolism in the patient with cancer: focus on burden of disease and benefits of thromboprophylaxis.

Authors:  Gary H Lyman
Journal:  Cancer       Date:  2010-11-08       Impact factor: 6.860

5.  Effectiveness and safety of expanded perioperative thromboprophylaxis in complex gynecologic surgery.

Authors:  Bradley R Corr; Andrea M Winter; Mary D Sammel; Christina S Chu; Brian F Gage; Andrea R Hagemann
Journal:  Gynecol Oncol       Date:  2015-07-14       Impact factor: 5.482

6.  Risk factors for perioperative venous thromboembolism: A retrospective study in Japanese women with gynecologic diseases.

Authors:  Nao Suzuki; Norihito Yoshioka; Tatsuru Ohara; Noriyuki Yokomichi; Takafumi Nako; Namiko Yahagi; Suguru Igarashi; Yoichi Kobayashi; Misako Yoshimatsu; Kenji Takizawa; Yasuo Nakajima; Kazushige Kiguchi; Bunpei Ishizuka
Journal:  Thromb J       Date:  2010-11-07

7.  Venous thromboembolism (VTE) rates following the implementation of extended duration prophylaxis for patients undergoing surgery for gynecologic malignancies.

Authors:  Kathleen M Schmeler; Ginger L Wilson; Katherine Cain; Mark F Munsell; Pedro T Ramirez; Pamela T Soliman; Alpa M Nick; Michael Frumovitz; Robert L Coleman; Michael H Kroll; Charles F Levenback
Journal:  Gynecol Oncol       Date:  2012-11-28       Impact factor: 5.482

8.  Different combination strategies for prophylaxis of venous thromboembolism in patients: A prospective multicenter randomized controlled study.

Authors:  Cui-Qin Sang; Na Zhao; Jian Zhang; Shu-Zhen Wang; Shu-Li Guo; Shu-Hong Li; Ying Jiang; Bin Li; Jian-Liu Wang; Lei Song; Jian-Jun Zhai; Zhen-Yu Zhang
Journal:  Sci Rep       Date:  2018-05-29       Impact factor: 4.379

9.  Efficacy of pre-operative pharmacologic thromboprophylaxis on incidence of venous thromboembolism following major gynecologic and gynecologic oncology surgery: a systematic review and meta-analysis.

Authors:  Steven Bisch; Rachelle Findley; Christina Ince; Maria Nardell; Gregg Nelson
Journal:  Int J Gynecol Cancer       Date:  2020-11-19       Impact factor: 3.437

10.  Effect of ovarian tumor characteristics on venous thromboembolic risk.

Authors:  Arvind Bakhru
Journal:  J Gynecol Oncol       Date:  2013-01-08       Impact factor: 4.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.